Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$191M |
| 2 |
Nike
NKE
|
+$190M |
| 3 |
UnitedHealth
UNH
|
+$158M |
| 4 |
Shopify
SHOP
|
+$153M |
| 5 |
TSMC
TSM
|
+$151M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palantir
PLTR
|
+$910M |
| 2 |
Microsoft
MSFT
|
+$668M |
| 3 |
Meta Platforms (Facebook)
META
|
+$351M |
| 4 |
Micron Technology
MU
|
+$244M |
| 5 |
Apple
AAPL
|
+$191M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.86% |
| 2 | Healthcare | 15.8% |
| 3 | Consumer Discretionary | 14.09% |
| 4 | Financials | 8.97% |
| 5 | Industrials | 8.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3176
Annaly Capital Management
NLY
$17.6B
| $194K | ﹤0.01% |
10,600
-1,792,415
| -99% | -$35M |
|
3177
CryoPort
CYRX
$766M
| $194K | ﹤0.01% |
+24,909
| New | +$186K |
|
3178
Cohen & Co
COHN
$38.7M
| $194K | ﹤0.01% |
18,700
+300
| +2% | +$2.9K |
|
3179
The Beachbody Company
BODI
$47.6M
| $194K | ﹤0.01% |
31,464
+300
| +1% | +$1.93K |
|
3180
Hycroft Mining Holding Corp
HYMC
$2.48B
| $192K | ﹤0.01% |
86,679
+11,200
| +15% | +$26.5K |
|
3181
First Seacoast Bancorp
FSEA
$80.4M
| $191K | ﹤0.01% |
19,032
+8,500
| +81% | +$79.2K |
|
|
OCFT
3182
DELISTED
OneConnect Financial Technology
OCFT
| $190K | ﹤0.01% |
78,160
-1,100
| -1% | -$2.85K |
|
|
AHG
3183
Akso Health Group
AHG
$1.11B
| $190K | ﹤0.01% |
139,398
-13,200
| -9% | -$13.3K |
|
|
NYXH
3184
Nyxoah
NYXH
$158M
| $187K | ﹤0.01% |
+23,400
| New | +$204K |
|
3185
SIFCO Industries
SIF
$121M
| $187K | ﹤0.01% |
52,734
+7,900
| +18% | +$30.7K |
|
3186
Hyperfine
HYPR
$94.7M
| $187K | ﹤0.01% |
212,300
+52,500
| +33% | +$50.5K |
|
3187
Enlivex Ltd
ENLV
$28.4M
| $186K | ﹤0.01% |
10,599
+5,613
| +113% | +$109K |
|
3188
Coda Octopus Group
CODA
$115M
| $186K | ﹤0.01% |
23,751
+13,737
| +137% | +$117K |
|
|
CNTB
3189
Connect Biopharma Holdings
CNTB
$160M
| $186K | ﹤0.01% |
134,697
-40,803
| -23% | -$47K |
|
|
RGLS
3190
DELISTED
Regulus Therapeutics
RGLS
| $185K | ﹤0.01% |
117,100
+19,900
| +20% | +$30.6K |
|
3191
HeartCore Enterprises
HTCR
$3.55M
| $185K | ﹤0.01% |
+5,090
| New | +$127K |
|
|
SACH
3192
Sachem Capital Corp
SACH
$37.6M
| $185K | ﹤0.01% |
136,706
+72,806
| +114% | +$137K |
|
3193
Senti Biosciences Holdings
SNTI
$12M
| $181K | ﹤0.01% |
+51,600
| New | +$165K |
|
3194
SCYNEXIS
SCYX
$50.9M
| $180K | ﹤0.01% |
18,638
+425
| +2% | +$4.41K |
|
3195
ProKidney
PROK
$289M
| $178K | ﹤0.01% |
105,200
+59,000
| +128% | +$106K |
|
3196
Escalade
ESCA
$287M
| $178K | ﹤0.01% |
12,430
+800
| +7% | +$11.6K |
|
|
TMQ
3197
Trilogy Metals
TMQ
$653M
| $177K | ﹤0.01% |
152,752
-18,248
| -11% | -$16.4K |
|
3198
Lipocine
LPCN
$17M
| $176K | ﹤0.01% |
36,032
-4,300
| -11% | -$21.8K |
|
|
TOUR
3199
Tuniu
TOUR
$54.4M
| $175K | ﹤0.01% |
17,193
-30
| -0.2% | -$334 |
|
3200
Neonode
NEON
$14.8M
| $173K | ﹤0.01% |
+21,074
| New | +$162K |
|
Similar funds
Jim Simons's Q4 2024 Portfolio in Review
As of Q4 2024, Jim Simons held 4,032 positions worth $67.6B, up 1.6% from $66.5B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Jim Simons's Q4 2024 filing shows 548 new, 1,485 increased, 1,480 reduced and 497 closed positions. Its largest new stake was UnitedHealth: 278,658 shares worth $141M. The largest sale was Palantir, an estimated $910M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jim Simons's largest Q4 2024 buy was UnitedHealth: 278,658 shares worth $141M.
- Jim Simons added most to Alibaba in Q4 2024, an estimated $191M increase.
- Jim Simons's biggest Q4 2024 reduction was Palantir, cutting an estimated $910M.
- Jim Simons fully exited Arm in Q4 2024, selling an estimated $153M.
- Jim Simons's ten largest holdings make up 10% of its $67.6B portfolio in Q4 2024.
- Jim Simons opened 548 new positions and closed 497 in Q4 2024.
- Jim Simons's portfolio value rose 1.6% quarter-over-quarter to $67.6B.
Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.